Get the Stockscreener App
1.185
5.20%
-0.065
Repare Therapeutics Inc stock is traded at $1.185, with a volume of 108.35K.
It is down -5.20% in the last 24 hours and down -14.13% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
See More
Previous Close:
$1.25
Open:
$1.25
24h Volume:
108.35K
Relative Volume:
0.25
Market Cap:
$53.14M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.5314
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
-2.87%
1M Performance:
-14.13%
6M Performance:
-60.10%
1Y Performance:
-84.87%
1-Day Range:
$1.175
$1.307
1-Week Range:
$1.1726
$1.32
52-Week Range:
$1.10
$8.49
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.185 | 53.14M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics Inc’s Banking’s 100-Day Moving Average at 2.6363: Will the Stock Break Through? - The InvestChronicle
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges - MSN
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Repare Therapeutics (RPTX) Stock Price, News & Analysis - MarketBeat
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
CNL Partners With Repare And Defence Therapeutics For Cancer Research - Canadian Manufacturing
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Financial Post
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Yahoo Finance
Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3% - MarketBeat
The Market Doesn't Like What It Sees From Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Repare Therapeutics Announces Strategic Changes and Financial Update - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC - Defense World
Stifel cuts Repare Therapeutics target to $3, maintains Buy By Investing.com - Investing.com Canada
Repare Therapeutics stock rating cut to Hold at Bloom Burton By Investing.com - Investing.com Canada
Repare Therapeutics Shifts Focus to Phase 1 Programs - TipRanks
Repare cans plans for phase 3 cancer combo trial in latest money-saving move - Fierce Biotech
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment - MarketWatch
Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring - StockTitan
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
Repare Therapeutics stock hits 52-week low at $1.22 - Investing.com
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com
Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Promising trial results for Repare's cancer drug combo - Investing.com India
Repare stock tanks 38% after Phase 1 data release - MSN
Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Repare Therapeutics Inc Stock (RPTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Segal Lloyd Mitchell | PRESIDENT AND CEO |
Apr 01 '24 |
Sale |
4.63 |
2,491 |
11,533 |
107,558 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Sale |
4.62 |
825 |
3,812 |
45,564 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Apr 01 '24 |
Sale |
4.61 |
789 |
3,637 |
44,775 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Sale |
4.64 |
450 |
2,088 |
72,318 |
| Zinda Michael | EVP, CHIEF SCIENTIFIC OFFICER |
Apr 01 '24 |
Sale |
4.66 |
410 |
1,911 |
71,908 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Mar 28 '24 |
Sale |
4.64 |
500 |
2,320 |
231,709 |
| Koehler Maria | EVP, CHIEF MEDICAL OFFICER |
Apr 01 '24 |
Sale |
4.66 |
300 |
1,398 |
231,409 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 25 '24 |
Sale |
4.79 |
825 |
3,952 |
43,862 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 27 '24 |
Sale |
4.62 |
825 |
3,812 |
42,212 |
| Forte Steve | EVP, CHIEF FINANCIAL OFFICER |
Mar 26 '24 |
Sale |
4.60 |
825 |
3,795 |
43,037 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):